deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT02270632

A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.

Sponsor: Philogen S.p.A.

Updated 10 times since 2017 Last updated: Jun 9, 2023 Started: Oct 1, 2014 Primary completion: Apr 30, 2019 Completion: Jun 8, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Approvals of new agents for the same indication have significantly slowed down the recruitment in this trial making the prosecution of the present investigation extremely difficult.

A PHASE2 clinical study on Rheumatoid Arthritis, this trial is terminated or withdrawn. The trial is conducted by Philogen S.p.A. and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotRecruiting~Nov 2018 – ~Jan 2021 · 26 months · monthly snapshotUnknown Status~Jan 2021 – ~May 2022 · 16 months · monthly snapshotUnknown Status~May 2022 – ~May 2023 · 12 months · monthly snapshotActive Not Recruiting~May 2023 – ~Jul 2023 · 2 months · monthly snapshotActive Not Recruiting~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 8 months · monthly snapshotTerminated

Change History

10 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not RecruitingTerminated

  5. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

Show 5 earlier versions
  1. May 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown StatusActive Not Recruiting

  2. Jan 2021 — May 2022 [monthly]

    Unknown Status PHASE2

  3. Nov 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

    Status: RecruitingUnknown Status

  4. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Philogen S.p.A.
Data source: Philogen S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .